https://www.onclive.com/conference-coverage/ash-2017/dr-rogers-discusses-early-intervention-with-ibrutinib-in-cll
Dr. Rogers Discusses Early Intervention With Ibrutinib in CLL

Kerry Rogers, MD


Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Having CLL, whether or not is has been treated, puts people at risk for secondary cancers and a higher rate of infection. As targeted agents become developed, the question becomes whether early intervention with these agents, like ibrutinib, can help patients avoid infectious complications, Rogers explains.
 
Printer Printing...